具有心血管获益的降糖药作为人类生活史关键要素的调节剂
本文为个人观点文章,基于生活史理论提出假说:GLP-1受体激动剂和SGLT2抑制剂通过减重和潜在对抗低度炎症的作用,可能减少肥胖驱动的维持成本和用于抑制低度炎症的消耗,从而介导其降糖之外的心血管获益。
要点
- 生活史理论认为能量在维持、生长、繁殖和防御病原体间权衡分配。
- GLP-1受体激动剂和SGLT2抑制剂可减重并可能对抗低度炎症。
- 作者假说:这些药物心血管获益可能由减少维持成本和炎症防御消耗介导。
核心结论
- 作者提出假说:GLP-1受体激动剂和SGLT2抑制剂的心血管获益可能由减少肥胖驱动的维持成本和用于抑制低度炎症的消耗所介导。
研究设计与样本
- 本文为个人观点文章,未报告系统检索范围或样本量。
主要发现
- 生活史理论假设所有生物在选择性压力下获取外部资源并分配以最大化适合度。
- 能量权衡跨越维持、生长、繁殖和防御病原体四项功能。
- GLP-1受体激动剂和SGLT2抑制剂可减轻体重并具有对抗低度炎症的潜力。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The life history theory assumes that all organisms are under selective pressure to harvest external resources and allocate them to maximise fitness: only organisms making the best use of energy obtain the greatest fitness benefits. The trade-off of energy spans four functions: maintenance, growth, reproduction, and defence against pathogens. The innovative antihyperglycaemic agents glucagon-like peptide 1 (GLP-1) receptor agonists and sodium-glucose cotransporter 2 (SGLT2) inhibitors decrease bodyweight and have the potential to counter low-grade inflammation. These key activities could rewire two components of the life history theory operative in adulthood-ie, maintenance and defence. In this Personal View, we postulate that the benefits of these medications on the cardiovascular system, beyond their glucose-lowering effects, could be mediated by the reduction of the maintenance cost driven by obesity and efforts spent on blunting low-grade inflammation.
引用
- Avogaro A, de Kreutzenberg SV, Morieri ML, et al. Glucose-lowering drugs with cardiovascular benefits as modifiers of critical elements of the human life history. Lancet Diabetes Endocrinol. 2022. PMID: 36182702. doi:10.1016/S2213-8587(22)00247-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。